Vilnius-based Biomatter has closed a €16.3 million Series A (about $18 million, ECB rate 13 November) led by Astanor, with existing investors UVC Partners, Inventure and Metaplanet following on, according to a release published by UnternehmerTUM on 12 November 2026.
The company says it has delivered more than 50 custom enzymes to more than 25 industrial customers in Europe, the US and Japan, naming AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. It says several relationships have grown from single projects into multi-year, multi-enzyme programmes. These are company claims; no revenue figure was published.
The money goes into a 2,000 square metre design and testing facility in Vilnius, due to open in 2027, which the company says should cut programme cycles from weeks to days. It will also expand its commercial team and US presence, where about half its customers sit. Chief executive Laurynas Karpus told BioXconomy that the round went to "a short list of funds with real depth in food, agriculture and industrial biotech", adding: "It is much easier to raise with customers than with a platform."
Why it matters
Food and ingredient groups buy enzymes for sugar processing, dairy, fermentation and specialty carbohydrates, and two named customers, Tereos and Kirin, sit in that world. Karpus's point is the one most AI biology pitches dodge: a platform story is hard to judge, a returning customer is easy. Investors should still separate services revenue from royalties, because custom design work scales with headcount unless the enzymes earn per tonne in the customer's plant. R&D teams should ask who owns the sequence and the improvement data. The diligence question: what share of revenue comes from repeat, multi-year programmes, and does any contract pay on the customer's production volume?
Sources and reporting
- Biomatter release via UnternehmerTUM: Biomatter schließt Series A über 18 Mio. USD ab, 12 November 2026
- COBALT: advised Astanor on Biomatter's USD 18 million Series A funding round
- BioXconomy: Biomatter banks $18m to turn enzyme design into an order-and-deliver business, 13 November 2026
Reporting note: Desk report on the UnternehmerTUM release of 12 November 2026, a COBALT deal note confirming the US$18 million figure and Astanor's lead, and BioXconomy coverage of 13 November 2026 (source of the Karpus quotes). The euro figure uses the ECB reference rate of 13 November 2026 (EUR 1 = USD 1.1052); US$18 million is about €16.3 million. FoodEdge has not spoken to Biomatter or seen its financials.
AI tools supported source research and drafting during the editorial process.


